This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vivus Weight-Loss Drug's Failing Math

Stocks in this article: VVUS ARNA OREX

MOUNTAIN VIEW, Calif. ( TheStreet) -- It's only been six weeks, but the commercial launch of Vivus' (VVUS) weight-loss pill Qsymia is already falling well below Wall Street expectations.

Admittedly, it's too early to call the Qsymia launch a total bust and Vivus has cautioned investors to expect a slow rollout. But based on prescription data collected so far, Vivus is highly unlikely to meet the $25 million in Qsymia sales that analysts have forecast for the fourth quarter -- the first significant barometer of the weight-loss drug's launch.

Vivus shares are down 12% to $15.38 in Wednesday trading.

The Qsymia launch math doesn't look pretty:

Doctors have written 5,802 new prescriptions for Qsymia in the five weeks since the drug launched (Sept. 21 through Oct. 19), according to healthcare research firm IMS Health.

Vivus has recommended that doctors write two Qsymia prescriptions for each new patient -- one at the low, titration dose and the second at the middle, recommended dose. Not all doctors are following this advice but roughly speaking, dividing total new Qsymia prescriptions in half gives you an estimate for the actual number of patients.

Through Oct. 19 -- or roughly one-third of the way through the fourth quarter -- there are approximately 2,901 patients on Qsymia, according to IMS data.

That's bad because the fourth-quarter Qsymia consensus sales estimate of $24.5 million (from Bloomberg with 12 analysts contributing forecasts) implies an average of 59,600 patients on the drug.

Qsymia is priced at approximately $4.50 per day, or $137 per month, or $411 per quarter per patient.

To be fair to Vivus, these are back-of-the-envelope calculations and data providers like IMS are not capturing all Qsymia prescriptions. But even if you upsize assumptions -- let's say there are 5,000 patients on Qsymia in October and that numbers doubles in November and doubles again in December -- Vivus still won't come close to $25 million in Qsymia sales.

Credit Suisse analyst Lee Kalowski is forecasting $12 million in fourth-quarter Qsymia sales, which I believe is the low estimate on the Street. Based on the current trajectory of new patient starts, Vivus will be hard-pressed to meet Kalowski's conservative forecast.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs